Strides Pharma Intl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for STRIDES PHARMA INTL
STRIDES PHARMA INTL has one hundred and ten approved drugs.
There are five US patents protecting STRIDES PHARMA INTL drugs.
Summary for Strides Pharma Intl
| US Patents: | 5 |
| Tradenames: | 75 |
| Ingredients: | 72 |
| NDAs: | 110 |
Drugs and US Patents for Strides Pharma Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Intl | DOXYCYCLINE | doxycycline | CAPSULE;ORAL | 065055-001 | Dec 1, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Strides Pharma Intl | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 076161-001 | Jun 10, 2004 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Strides Pharma Intl | IBUPROFEN | ibuprofen | TABLET;ORAL | 071575-001 | May 8, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Strides Pharma Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Strides Pharma Intl | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 6,143,775 | ⤷ Start Trial |
| Strides Pharma Intl | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 4,859,692 | ⤷ Start Trial |
| Strides Pharma Intl | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 4,859,692 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for STRIDES PHARMA INTL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
International Patents for Strides Pharma Intl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112022001591 | ⤷ Start Trial |
| China | 114450002 | ⤷ Start Trial |
| European Patent Office | 4003323 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Strides Pharma Intl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0502314 | C300095 | Netherlands | ⤷ Start Trial | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 2236132 | 300714 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718 |
| 0454511 | 99C0009 | Belgium | ⤷ Start Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
